Does the media favor IMCR or COGT?

In the previous week, Cogent Biosciences had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Immunocore. Cogent Biosciences' average media sentiment score of 0.68 beat Immunocore's score of 0.33 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMCR or PTCT?

In the previous week, PTC Therapeutics had 5 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for PTC Therapeutics and 1 mentions for Immunocore. PTC Therapeutics' average media sentiment score of 1.44 beat Immunocore's score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BLTE or IMCR more profitable?

Belite Bio has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Immunocore -6.68% -7.07% -2.55%

Does the media refer more to BLTE or IMCR?

In the previous week, Belite Bio had 2 more articles in the media than Immunocore. MarketBeat recorded 3 mentions for Belite Bio and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.33 beat Belite Bio's score of 0.00 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LEGN or IMCR?

In the previous week, Legend Biotech had 11 more articles in the media than Immunocore. MarketBeat recorded 12 mentions for Legend Biotech and 1 mentions for Immunocore. Legend Biotech's average media sentiment score of 0.59 beat Immunocore's score of 0.33 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, GRFS or IMCR?

Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.59 $454.82M $0.19 38.58 Immunocore $400.02M 3.52 -$35.51M -$0.55 N/A

Is GRFS or IMCR more profitable?

Grifols has a net margin of 5.54% compared to Immunocore's net margin of -6.68%. Grifols' return on equity of 6.21% beat Immunocore's return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Immunocore -6.68% -7.07% -2.55%

Does the media prefer GRFS or IMCR?

In the previous week, Grifols had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Grifols and 1 mentions for Immunocore. Grifols' average media sentiment score of 1.64 beat Immunocore's score of 0.33 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Immunocore (IMCR) Competitors

$27.79 -0.50 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$28.35 +0.56 (+2.02%)

As of 07:56 PM Eastern

Compare

IMCR vs. COGT, PTCT, BLTE, LEGN, and GRFS

Should you buy Immunocore stock or one of its competitors? MarketBeat compares Immunocore with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunocore include Cogent Biosciences (COGT), PTC Therapeutics (PTCT), Belite Bio (BLTE), Legend Biotech (LEGN), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Immunocore compare to Cogent Biosciences?

Immunocore (NASDAQ:IMCR) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

84.5% of Immunocore shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cogent Biosciences had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Immunocore. Cogent Biosciences' average media sentiment score of 0.68 beat Immunocore's score of 0.33 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunocore has higher revenue and earnings than Cogent Biosciences. Immunocore is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Immunocore currently has a consensus target price of $56.71, indicating a potential upside of 104.08%. Cogent Biosciences has a consensus target price of $43.73, indicating a potential upside of 40.33%. Given Immunocore's higher probable upside, equities research analysts plainly believe Immunocore is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Immunocore beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Immunocore compare to PTC Therapeutics?

Immunocore (NASDAQ:IMCR) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunocore presently has a consensus target price of $56.71, suggesting a potential upside of 104.08%. PTC Therapeutics has a consensus target price of $89.00, suggesting a potential upside of 25.58%. Given Immunocore's higher probable upside, research analysts plainly believe Immunocore is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, PTC Therapeutics had 5 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for PTC Therapeutics and 1 mentions for Immunocore. PTC Therapeutics' average media sentiment score of 1.44 beat Immunocore's score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Immunocore has a net margin of -6.68% compared to PTC Therapeutics' net margin of -22.58%. Immunocore's return on equity of -7.07% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

PTC Therapeutics has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A
PTC Therapeutics	$1.73B	3.40	$682.64M	-$2.33	N/A

Summary

Immunocore beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Immunocore compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Immunocore	-6.68%	-7.07%	-2.55%

Belite Bio has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A

In the previous week, Belite Bio had 2 more articles in the media than Immunocore. MarketBeat recorded 3 mentions for Belite Bio and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.33 beat Belite Bio's score of 0.00 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio presently has a consensus price target of $203.00, indicating a potential upside of 45.38%. Immunocore has a consensus price target of $56.71, indicating a potential upside of 104.08%. Given Immunocore's higher probable upside, analysts plainly believe Immunocore is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Immunocore beats Belite Bio on 11 of the 16 factors compared between the two stocks.

How does Immunocore compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Legend Biotech currently has a consensus target price of $60.23, suggesting a potential upside of 91.09%. Immunocore has a consensus target price of $56.71, suggesting a potential upside of 104.08%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Legend Biotech has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

In the previous week, Legend Biotech had 11 more articles in the media than Immunocore. MarketBeat recorded 12 mentions for Legend Biotech and 1 mentions for Immunocore. Legend Biotech's average media sentiment score of 0.59 beat Immunocore's score of 0.33 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore has lower revenue, but higher earnings than Legend Biotech. Immunocore is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.69	-$296.80M	-$0.68	N/A
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A

Immunocore has a net margin of -6.68% compared to Legend Biotech's net margin of -21.98%. Immunocore's return on equity of -7.07% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Immunocore	-6.68%	-7.07%	-2.55%

Summary

Immunocore beats Legend Biotech on 10 of the 17 factors compared between the two stocks.

How does Immunocore compare to Grifols?

Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

84.5% of Immunocore shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Grifols presently has a consensus target price of $10.00, indicating a potential upside of 36.43%. Immunocore has a consensus target price of $56.71, indicating a potential upside of 104.08%. Given Immunocore's stronger consensus rating and higher possible upside, analysts clearly believe Immunocore is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Grifols has a net margin of 5.54% compared to Immunocore's net margin of -6.68%. Grifols' return on equity of 6.21% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Immunocore	-6.68%	-7.07%	-2.55%

Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.59	$454.82M	$0.19	38.58
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A

In the previous week, Grifols had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Grifols and 1 mentions for Immunocore. Grifols' average media sentiment score of 1.64 beat Immunocore's score of 0.33 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grifols has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Summary

Grifols beats Immunocore on 9 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCR vs. The Competition

Export

Metric	Immunocore	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.43B	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-50.53	18.61	23.92	23.74
Price / Sales	3.52	298.40	507.55	107.95
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.70	8.04	10.28	6.78
Net Income	-$35.51M	$23.89M	$3.57B	$337.51M
7 Day Performance	-4.60%	-5.97%	-1.43%	-2.72%
1 Month Performance	-6.05%	2.78%	3.27%	1.87%
1 Year Performance	-25.40%	36.26%	23.37%	26.60%

Immunocore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCR Immunocore	2.8144 of 5 stars	$27.79 -1.8%	$56.71 +104.1%	-24.1%	$1.43B	$400.02M	N/A	320
COGT Cogent Biosciences	3.2852 of 5 stars	$33.52 +2.6%	$43.73 +30.5%	+356.2%	$5.73B	N/A	N/A	80	Gap Up
PTCT PTC Therapeutics	3.6329 of 5 stars	$67.46 -2.0%	$88.36 +31.0%	+36.1%	$5.60B	$827.11M	N/A	1,410	News Coverage Positive News
BLTE Belite Bio	2.5946 of 5 stars	$136.79 -0.4%	$203.80 +49.0%	+140.2%	$5.47B	N/A	N/A	10
LEGN Legend Biotech	4.104 of 5 stars	$29.34 -0.1%	$59.00 +101.1%	-6.8%	$5.43B	$1.03B	N/A	2,965

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCR) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Competitors

IMCR vs. COGT, PTCT, BLTE, LEGN, and GRFS

How does Immunocore compare to Cogent Biosciences?

Summary

How does Immunocore compare to PTC Therapeutics?

Summary

How does Immunocore compare to Belite Bio?

Summary

How does Immunocore compare to Legend Biotech?

Summary

How does Immunocore compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Competitors

IMCR vs. COGT, PTCT, BLTE, LEGN, and GRFS

How does Immunocore compare to Cogent Biosciences?

Do insiders & institutionals believe in IMCR or COGT?

Does the media favor IMCR or COGT?

Which has stronger earnings & valuation, IMCR or COGT?

Do analysts rate IMCR or COGT?

Which has more risk and volatility, IMCR or COGT?

Is IMCR or COGT more profitable?

Summary

How does Immunocore compare to PTC Therapeutics?

Do insiders and institutionals hold more shares of IMCR or PTCT?

Do analysts rate IMCR or PTCT?

Does the media refer more to IMCR or PTCT?

Which has more risk & volatility, IMCR or PTCT?

Is IMCR or PTCT more profitable?

Which has better earnings & valuation, IMCR or PTCT?

Summary

How does Immunocore compare to Belite Bio?

Do institutionals and insiders believe in BLTE or IMCR?

Is BLTE or IMCR more profitable?

Which has more risk and volatility, BLTE or IMCR?

Which has preferable valuation and earnings, BLTE or IMCR?

Does the media refer more to BLTE or IMCR?

Do analysts rate BLTE or IMCR?

Summary

How does Immunocore compare to Legend Biotech?

Do analysts rate LEGN or IMCR?

Do insiders & institutionals hold more shares of LEGN or IMCR?

Which has more risk and volatility, LEGN or IMCR?

Does the media refer more to LEGN or IMCR?

Which has preferable earnings & valuation, LEGN or IMCR?

Is LEGN or IMCR more profitable?

Summary

How does Immunocore compare to Grifols?

Do insiders and institutionals believe in GRFS or IMCR?

Do analysts rate GRFS or IMCR?

Is GRFS or IMCR more profitable?

Which has better earnings & valuation, GRFS or IMCR?

Does the media prefer GRFS or IMCR?

Which has more risk & volatility, GRFS or IMCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools